How NABH Accreditation Influences Clinical Trial Site Selection in India

Introduction

Site selection is a critical determinant of clinical trial success, especially in a diverse and complex healthcare environment like India. One key metric that has gained increasing importance is NABH accreditation. The National Accreditation Board for Hospitals and Healthcare Providers (NABH) plays a significant role in enhancing the quality and reliability of healthcare institutions involved in clinical research. Sponsors and Contract Research Organizations (CROs) are increasingly prioritizing NABH-accredited hospitals for site selection, particularly in trials demanding high regulatory compliance and patient safety standards.

This article explores the role of NABH accreditation in clinical trial site selection in India. It outlines the regulatory framework, key operational advantages, challenges, and strategies to integrate NABH certification into site feasibility assessments.

Background / Regulatory Framework

What is NABH Accreditation?

The NABH is a constituent board of the Quality Council of India (QCI), established to set benchmarks for quality and safety in healthcare institutions. Its accreditation system evaluates hospitals based on a comprehensive set of performance standards covering patient rights, infection control, documentation practices, infrastructure, and clinical governance.

CDSCO Guidelines and NDCTR 2019

Under the New Drugs and Clinical Trials Rules (NDCTR), 2019, the CDSCO mandates that trial sites must have qualified investigators, an operational Ethics Committee (registered with CDSCO), and adequate infrastructure to conduct clinical studies. While NABH accreditation is not a regulatory requirement, it acts as a strong proxy for compliance readiness and operational maturity.

Global Regulatory Influence

International sponsors operating in India often align site selection criteria with standards laid out by ICH-GCP, EMA, and US FDA. NABH accreditation aligns well with these expectations, especially in relation to patient safety, SOP compliance, and quality system maturity.

Core Clinical Trial Insights

Why NABH Accreditation Matters in Site Selection

NABH-accredited hospitals demonstrate consistent performance in several areas critical to clinical trial success:

• Trained Staff: NABH standards require periodic training in SOPs, patient safety, and documentation.
• Ethics Committee Oversight: Accredited institutions often have internal ECs that are well-versed in GCP and regulatory guidelines.
• Data Management Infrastructure: NABH emphasizes proper recordkeeping, EMR integration, and data confidentiality, reducing compliance risks.
• Patient-Centric Practices: Informed consent processes, grievance redressal systems, and patient engagement practices are well-structured.

Comparison: NABH vs Non-NABH Sites

Feasibility Assessment Enhancements

Sponsors and CROs evaluating potential sites in India can include NABH status as a core feasibility criterion. Commonly assessed aspects include:

• Number of beds, ICU capacity, and diagnostic services
• Investigator experience and GCP certification
• Quality management systems and deviation handling
• Digital systems for source documentation and eCRFs
• Internal SOPs aligned with ICH-GCP

Role in Regulatory Inspections and Audit Readiness

NABH-accredited institutions are better equipped for sponsor and regulatory audits. The structured processes mandated by NABH—including audit trail maintenance, document control, and CAPA systems—enhance the site’s inspection readiness for CDSCO, EMA, or US FDA inspections.

Patient Recruitment and Retention Advantages

NABH sites often have:

• Established catchment areas with demographic data
• Referral networks from affiliated primary care centers
• Patient education departments and counselors
• Higher patient trust due to brand recognition

Alignment with GCP and Global Quality Systems

NABH standards intersect well with ICH-GCP pillars:

• Ethics: Strong informed consent documentation, conflict-of-interest policies
• Data Integrity: Defined processes for source documentation, backups, and access control
• Monitoring: Trained staff who understand roles in SDV, monitoring visits

Best Practices & Preventive Measures

• Include NABH accreditation as a site selection checklist item in feasibility questionnaires.
• Verify the accreditation validity period and scope (entry-level vs full NABH).
• Engage ECs from NABH sites during protocol design for ethical review quality.
• Request site SOPs aligned with GCP and CDSCO inspection history.
• Provide site-specific training to harmonize sponsor SOPs with NABH systems.

Scientific & Regulatory Evidence

• NDCTR 2019: Site infrastructure and EC requirements
• NABH 5th Edition Hospital Accreditation Standards
• ICH-GCP E6 (R2): Investigator responsibilities, data integrity, quality systems
• Quality Council of India (QCI): Accreditation principles and procedures

Special Considerations

Decentralized Trials and NABH Sites

NABH-accredited hospitals with telemedicine capabilities, e-consent integration, and remote monitoring readiness are preferred for decentralized or hybrid trials.

Public vs Private NABH Hospitals

While many private hospitals in Tier-1 cities hold NABH accreditation, public institutions like AIIMS and PGI are also entering the accredited space. Sponsors should balance reach with compliance readiness when choosing such sites.

Tier-2 City Expansion

Many NABH-accredited hospitals are emerging in Tier-2 cities like Bhopal, Kochi, and Vadodara—offering lower recruitment competition and high compliance environments for sponsors.

When Sponsors Should Prioritize NABH Sites

• Trials involving high-risk interventions (oncology, gene therapy)
• Studies targeting international submission (FDA/EMA)
• New-to-India sponsors lacking prior CDSCO audit experience
• Early-phase trials requiring real-time documentation and safety oversight
• Multi-site studies with centralized GCP monitoring and audit teams

FAQs

1. Is NABH accreditation mandatory for clinical trial sites in India?

No. CDSCO does not mandate NABH accreditation, but it is a strong quality indicator preferred by many sponsors and CROs.

2. How many NABH-accredited hospitals currently conduct trials?

As of 2024, over 700 hospitals in India hold NABH accreditation, and approximately 150 actively participate in clinical trials across therapeutic areas.

3. Do NABH sites have better inspection outcomes?

Anecdotal evidence and sponsor audits suggest that NABH sites exhibit fewer major deviations and are better prepared for CDSCO or sponsor inspections.

4. Can non-NABH sites still be selected?

Yes, especially if they have strong investigators and infrastructure. However, additional site-specific training and audits may be needed.

5. Are NABH-accredited sites more expensive?

Some may charge premium site management fees due to infrastructure quality and staff training investments, but often offset by reduced rework and inspection failures.

6. How to verify NABH accreditation?

Check the NABH website (nabh.co) for the latest list of accredited hospitals, their scope, and validity period.

7. Does NABH cover EC quality?

Yes. NABH standards include assessment of EC functioning, SOPs, meeting frequency, conflict-of-interest policies, and training of members.

Conclusion

Incorporating NABH accreditation as a clinical trial site selection criterion in India provides measurable benefits in quality, compliance, and operational excellence. While not a regulatory requirement, NABH-accredited institutions align with global GCP standards, enhance audit readiness, and contribute to reliable trial conduct. As India’s clinical trial landscape expands, leveraging NABH as a quality marker will support more consistent and inspection-resilient trial execution.